Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Horcajada

Showing results (131-140 of 176) with videos related to

Pageof 18
Sort By:
Infectious Diseases (London, England)|August 30, 2024
Synergistic efficacy of ceftazidime/avibactam and aztreonam against carbapenemase-producing <i>Pseudomonas aeruginosa</i>: insights from the hollow-fiber infection modelMaría M Montero, Sandra Domene-Ochoa, Núria Prim, et al.
Clinical & Translational Immunology|September 10, 2021
SARS-CoV-2 sculpts the immune system to induce sustained virus-specific naïve-like and memory B-cell responsesLeire de Campos-Mata, Sonia Tejedor Vaquero, Roser Tachó-Piñot, et al.
Journal of Infection and Public Health|November 9, 2025
An international Delphi survey on priorities in antimicrobial resistant infections therapeutic research: A preliminary study of MePRAM projectFrancesco Cogliati Dezza, Paula Olivares Navarro, Maria Giulia Caponcello, et al.
Scientific Reports|January 22, 2015
A "green" strategy to construct non-covalent, stable and bioactive coatings on porous MOF nanoparticlesV Agostoni, P Horcajada, M Noiray, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 21, 2020
Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE TrialGeorge R Thompson, Alex Soriano, Athanasios Skoutelis, et al.
Clinical Microbiology Reviews|October 9, 2025
Current and future options for the treatment of serious infections due to carbapenem-resistant <i>Pseudomonas aeruginosa</i>Juan P Horcajada, Ana C Gales, Burcu Isler, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|August 25, 2025
How do I manage Difficult-to-Treat Pseudomonas aeruginosa infections?: Key Questions for Today's CliniciansJuan P Horcajada, Ana Gales, Burcu Isler, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|February 18, 2025
Addressing carbapenemase-producing extensively drug-resistant Pseudomonas aeruginosa: the potential of cefiderocol and ceftazidime/avibactam plus aztreonam therapyMaría Milagro Montero, Sandra Domene-Ochoa, Núria Prim, et al.
The Journal of Antimicrobial Chemotherapy|December 26, 2024
Penetration of linezolid into the pleural cavity in critically ill patients with proven or suspected Gram-positive bacterial infections: a retrospective pharmacokinetic studyMarta De Antonio-Cuscó, Luisa Sorlí, Rosana Muñoz-Bermúdez, et al.
Archives of Internal Medicine|September 24, 2008
Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coliJesús Rodríguez-Baño, Juan C Alcalá, Jose M Cisneros, et al.
Pageof 18

Showing results (131-140 of 176) with videos related to

Sort By:
Pageof 18
Infectious Diseases (London, England)|August 30, 2024
Synergistic efficacy of ceftazidime/avibactam and aztreonam against carbapenemase-producing <i>Pseudomonas aeruginosa</i>: insights from the hollow-fiber infection modelMaría M Montero, Sandra Domene-Ochoa, Núria Prim, et al.
Clinical & Translational Immunology|September 10, 2021
SARS-CoV-2 sculpts the immune system to induce sustained virus-specific naïve-like and memory B-cell responsesLeire de Campos-Mata, Sonia Tejedor Vaquero, Roser Tachó-Piñot, et al.
Journal of Infection and Public Health|November 9, 2025
An international Delphi survey on priorities in antimicrobial resistant infections therapeutic research: A preliminary study of MePRAM projectFrancesco Cogliati Dezza, Paula Olivares Navarro, Maria Giulia Caponcello, et al.
Scientific Reports|January 22, 2015
A "green" strategy to construct non-covalent, stable and bioactive coatings on porous MOF nanoparticlesV Agostoni, P Horcajada, M Noiray, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 21, 2020
Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE TrialGeorge R Thompson, Alex Soriano, Athanasios Skoutelis, et al.
Clinical Microbiology Reviews|October 9, 2025
Current and future options for the treatment of serious infections due to carbapenem-resistant <i>Pseudomonas aeruginosa</i>Juan P Horcajada, Ana C Gales, Burcu Isler, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|August 25, 2025
How do I manage Difficult-to-Treat Pseudomonas aeruginosa infections?: Key Questions for Today's CliniciansJuan P Horcajada, Ana Gales, Burcu Isler, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|February 18, 2025
Addressing carbapenemase-producing extensively drug-resistant Pseudomonas aeruginosa: the potential of cefiderocol and ceftazidime/avibactam plus aztreonam therapyMaría Milagro Montero, Sandra Domene-Ochoa, Núria Prim, et al.
The Journal of Antimicrobial Chemotherapy|December 26, 2024
Penetration of linezolid into the pleural cavity in critically ill patients with proven or suspected Gram-positive bacterial infections: a retrospective pharmacokinetic studyMarta De Antonio-Cuscó, Luisa Sorlí, Rosana Muñoz-Bermúdez, et al.
Archives of Internal Medicine|September 24, 2008
Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coliJesús Rodríguez-Baño, Juan C Alcalá, Jose M Cisneros, et al.
Pageof 18